DE69912827T2 - "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen - Google Patents

"ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen Download PDF

Info

Publication number
DE69912827T2
DE69912827T2 DE69912827T DE69912827T DE69912827T2 DE 69912827 T2 DE69912827 T2 DE 69912827T2 DE 69912827 T DE69912827 T DE 69912827T DE 69912827 T DE69912827 T DE 69912827T DE 69912827 T2 DE69912827 T2 DE 69912827T2
Authority
DE
Germany
Prior art keywords
lpa
production
presenting assembly
ligand presenting
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69912827T
Other languages
English (en)
Other versions
DE69912827D1 (de
Inventor
Arne Holm
Malene Jorgensen
Soren Ostergaard
Michael Theisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOKE DIAGNOSTICS APS, AARHUS, DK
Original Assignee
LOKE DIAGNOSTICS APS AARHUS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOKE DIAGNOSTICS APS AARHUS filed Critical LOKE DIAGNOSTICS APS AARHUS
Application granted granted Critical
Publication of DE69912827D1 publication Critical patent/DE69912827D1/de
Publication of DE69912827T2 publication Critical patent/DE69912827T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69912827T 1998-09-29 1999-09-29 "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen Expired - Lifetime DE69912827T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801233 1998-09-29
PCT/DK1999/000510 WO2000018791A1 (en) 1998-09-29 1999-09-29 Ligand presenting assembly (lpa), method of preparation and uses thereof

Publications (2)

Publication Number Publication Date
DE69912827D1 DE69912827D1 (de) 2003-12-18
DE69912827T2 true DE69912827T2 (de) 2004-10-21

Family

ID=8102501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912827T Expired - Lifetime DE69912827T2 (de) 1998-09-29 1999-09-29 "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen

Country Status (6)

Country Link
US (1) US20040086949A1 (de)
EP (1) EP1117677B1 (de)
AT (1) ATE254137T1 (de)
AU (1) AU6078399A (de)
DE (1) DE69912827T2 (de)
WO (1) WO2000018791A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242479A1 (en) 2001-08-17 2004-12-02 Elisabeth Bock Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
DE602004027508D1 (de) * 2003-08-07 2010-07-15 Enkam Pharmaceuticals As Lpa-haltige verbindungen
US20070172496A1 (en) * 2004-01-28 2007-07-26 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
EP2377884A1 (de) 2005-05-10 2011-10-19 Neoloch Aps Neuritogene peptide
US8618060B2 (en) 2006-02-14 2013-12-31 University Of Tasmania Metallothionein-derived peptide fragments
US20090285780A1 (en) * 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
EP2164992B1 (de) * 2007-05-30 2016-05-04 Lpath, Inc. Zusammensetzungen und verfahren zur bindung von lysophosphatidinsäure
US8470964B2 (en) 2007-11-28 2013-06-25 Enkam Pharmaceuticals A/S Peptides derived from NCAM (FGLs)
CN103229055A (zh) * 2010-09-27 2013-07-31 康奈尔大学 莱姆病的诊断方法
WO2014093196A1 (en) * 2012-12-10 2014-06-19 North Carolina State University Solid phase scaffold based libraries
WO2014147129A1 (en) * 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596792A (en) * 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
DE69718903T2 (de) * 1996-05-02 2003-12-04 Dakocytomation Denmark As Glos Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
CA2278200A1 (en) * 1997-01-29 1998-07-30 Nycomed Imaging As Polymers

Also Published As

Publication number Publication date
ATE254137T1 (de) 2003-11-15
EP1117677A1 (de) 2001-07-25
WO2000018791A1 (en) 2000-04-06
AU6078399A (en) 2000-04-17
DE69912827D1 (de) 2003-12-18
EP1117677B1 (de) 2003-11-12
US20040086949A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
ATE113604T1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
ATE246880T1 (de) Verfahren zur herstellung von phytosterol- oder phytostanol-mikropartikeln
ATE223413T1 (de) Neuartige verbindungen
RU93055882A (ru) Производные n-сульфонил-2-оксоиндола, способ их получения, исходные для их получения, фармацевтическая композиция на их основе
NZ527182A (en) Neisseria meningitidis antigens and compositions
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
ATE278390T1 (de) Verfahren zur herstellung von arzneistoffpartikeln
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE69912827D1 (de) "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
DE3854003D1 (de) Verfahren zur Herstellung von N-substituiertem Amin.
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
ATE293595T1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
ATE57694T1 (de) Verfahren zur herstellung von 2,5dicetopiperazinen.
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
DE3674582D1 (de) (s)-(-)-1-propyl-2',6'-pipecoloxylidid-hydrochloridmonohydrat, verfahren zu seiner herstellung und es enthaltendes pharmazeutisches praeparat.
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
FR2717081B1 (fr) Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
NO931905D0 (no) 8-en-19, 11beta-broede steroider, deres fremstilling og farmasoeytiske preparater inneholdende disse
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATA156590A (de) Mono-(2-ammonium-2-hydroxymethyl-1,3-propandiol (2r,cis)-1,2-epoxypropylphosphonat und verfahren zu dessen herstellung sowie pharmazeutische zusammensetzungen
DE69104220D1 (de) Verfahren zur Herstellung von direktkomprimierten, Cephalosporansäure Derivate enthaltendenTabletten.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LOKE DIAGNOSTICS APS, AARHUS, DK

8364 No opposition during term of opposition